The first case of blastic plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement

Leukemia Research

Volumn 36, Issue 1, 2012, Pages 117-118

  Toya, Takashi ^a   Nishimoto, Nahoko ^a   Koya, Junji ^a   Nakagawa, Masahiro ^a   Nakamura, Fumihiko ^a   Kandabashi, Koji ^a   Yamamoto, Go ^a   Nannya, Yasuhito ^a   Ichikawa, Motoshi ^a   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD123 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; MITOXANTRONE; PREDNISOLONE; STEM CELL FACTOR RECEPTOR; VINCRISTINE;

ADULT; ANAMNESIS; ANEMIA; ARTICLE; BLASTIC NK CELL LYMPHOMA; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; BLOOD; BONE MARROW; CANCER REGRESSION; CASE REPORT; CELL INFILTRATION; CHROMOSOME ADDITION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 19; CYTOGENETICS; DERMIS; DRUG TREATMENT FAILURE; ENL GENE; FLOW CYTOMETRY; GENE IDENTIFICATION; GENE REARRANGEMENT; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; LYMPHADENOPATHY; MALE; MLL GENE; NEUTROPENIA; ONCOGENE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PURPURA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT;

BASE SEQUENCE; BONE MARROW NEOPLASMS; DENDRITIC CELLS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; SEQUENCE HOMOLOGY, NUCLEIC ACID; SKIN NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 83555165000     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.029     Document Type: Article

References (10)

1. Garnache-Ottou F., Feuillard J., Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?. Br J Haematol 2007, 136:539-548.
2. Chaperot L., Bendriss N., Manches O., Gressin R., Maynadie M., Trimoreau F., et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001, 97:3210-3217.
3. Schoch C., Schnittger S., Klaus M., Kern W., Hiddemann W., Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003, 102:2395-2402.
4. Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A., et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995, 9:1783-1786.
5. Kern W., Aul C., Maschmeyer G., Schonrock-Nabulsi R., Ludwig W.D., Bartholomaus A., et al. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 1998, 12:1049-1055.
6. Reimer P., Rudiger T., Kraemer D., Kunzmann V., Weissinger F., Zettl A., et al. What is CD4+CD56+ malignancy and how should it be treated?. Bone Marrow Transplant 2003, 32:637-646.
7. Leroux D., Mugneret F., Callanan M., Radford-Weiss I., Dastugue N., Feuillard J., et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood 2002, 99:4154-4159.
8. Dijkman R., van Doorn R., Szuhai K., Willemze R., Vermeer M.H., Tensen C.P. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 2007, 109:1720-1727.
9. Bueno C., Almeida J., Lucio P., Marco J., Garcia R., de Pablos J.M., et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica 2004, 89:58-69.
10. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003, 17:3029-3035.